A phase I single escalating intravenous (IV) dose of MEDI 563, an anti-IL5Rα antibody, in atopic asthma
W. Busse, R. Katial, B. White, E. Gibiansky, A. Coyle, G. Spitalny, N. Molfino (Madison, WI, Denver, CO, Gaithersburg, MD, Princeton, NJ, United States Of America)
Source: Annual Congress 2008 - New treatments for asthma
Session: New treatments for asthma
Session type: Oral Presentation
Number: 3019
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
W. Busse, R. Katial, B. White, E. Gibiansky, A. Coyle, G. Spitalny, N. Molfino (Madison, WI, Denver, CO, Gaithersburg, MD, Princeton, NJ, United States Of America). A phase I single escalating intravenous (IV) dose of MEDI 563, an anti-IL5Rα antibody, in atopic asthma. Eur Respir J 2008; 32: Suppl. 52, 3019
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010
A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5Rα monoclonal antibody, in adult asthmatics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Dose- and exposure response analysis of glycopyrrolate (GP) metered dose inhaler (MDI) to support optimal dosing in patients with COPD for combination product development Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Phase 2, mutlicenter, double-blind study of CNTO 148, a human monoclonal anti-TNF α antibody, in symptomatic patients with severe persistent asthma Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007
Low-dose (100 μg, b.i.d. ) inhaled fluticasone propionate (FP) is as effective as high-dose (500 μg, b.i.d. ) in mild symptomatic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
High doses of omalizumab (OMA) in patients with allergic (IgE-mediated) asthma and IgE/body weight combinations outside the initially approved dosing table Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
Efficacy, safety and tolerability of 3 day azithromycin (A) versus 10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE) Source: Eur Respir J 2005; 26: Suppl. 49, 135s Year: 2005
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma Source: Eur Respir J 2013; 41: 330-338 Year: 2013
Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 457s Year: 2007
Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Bronchodilator response of single dose of tiotropium (Tio) plus formoterol (Formo) versus four doses of ipratopium (Ipra) plus salbutamol (Salb) over 24 hours in subjects with moderate-to-severe stable COPD Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment Year: 2008
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy at two UMEC doses in healthy subjects Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL) Source: International Congress 2017 – Management of COPD Year: 2017
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
Efficacy of fluticasone furoate (FF) and vilanterol (VI), separately and in combination (FF/VI), in an allergen challenge model Source: Annual Congress 2012 - Treatment of asthma, bronchiectasis and cough: inhaler use Year: 2012
Pharmacokinetic (PK) analysis of fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI) following triple therapy in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014
The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020